The Most Wasted Molecule on Earth -> The Most Wanted Molecule on Earth
The Methane Economy
Why the world’s most abundant waste gas is becoming biology’s most compelling feedstock.
Written by Sarah Rodriguez, PhD
The bigger picture
Methane is often described as the “low-hanging fruit” of climate mitigation. The greenhouse gas we could reduce fastest with the most immediate warming impact. But we think the better metaphor is that methane is a raw material hiding in plain sight: globally abundant, thermodynamically rich, and increasingly accessible to biological conversion. The companies that figure out how to use it, not just abate it, will build some of the most important industrial platforms of the next decade.
This distinction matters. The dominant framing of methane has been as a liability: something to capture, flare, plug, or regulate away. Bloomberg Philanthropies has committed $172 million to methane detection and monitoring since 2019, including a $100 million initiative announced at COP30 to scale satellite surveillance of super-emitters globally. The Global Methane Pledge, signed by over 150 countries, commits to at least a 30% reduction in anthropogenic methane emissions by 2030. These are important efforts. But detection and abatement are only half the equation. The real opportunity lies in manufacturing products from this gas rather than simply destroying it.
Biology’s methane engines
Over 570 million tonnes of methane are released into the atmosphere every year from landfills, livestock operations, oil and gas infrastructure, and wastewater treatment. Methane traps over 80 times more heat than CO₂ over a 20-year window, yet the Global Methane Hub estimates that only 2% of climate finance has targeted it. Most of it escapes because the sources are too dispersed, too contaminated, or too small-scale for conventional gas processing infrastructure.
Biology has the ability to change that.
Methanotrophs, bacteria that consume methane as their sole carbon and energy source, are emerging as a serious industrial platform. These organisms thrive naturally in wetlands, landfills, forest soils, and hot springs, using specialized enzymes to oxidize methane step-by-step under mild, low-energy conditions and naturally account for 43-80 MT of atmospherics methane removal per year. Scientists have studied them for decades. The difference now is our ability to engineer them.
Recent advances in genome editing, synthetic biology, and gas-phase bioreactor design are transforming methanotrophs from environmental curiosities into production hosts. Engineered methanotrophs can now produce single-cell protein (with an amino acid profile similar to fishmeal, already approved in EU salmon feed), biodegradable plastics (PHAs), methanol, and a growing list of specialty chemicals.
The economics
From an investment standpoint, methane-to-products has several structural advantages.
The feedstock is free, or nearly free. Methane from landfills, wastewater treatment, and oil and gas operations is currently vented or flared because existing infrastructure can’t economically process it. Companies that convert this stranded methane into products aren’t just reducing input costs, they’re getting paid to take the feedstock. This is the same economic logic that makes waste-feedstock approaches so powerful across bioindustrials.
The end markets are massive and established. Single-cell protein targets a $180B+ global animal feed market. Biobased fertilizers target a $190B+ market. Bio-based plastics target a $400B+ plastics market. Methanol is one of the most widely traded industrial chemicals on earth. These are not speculative markets waiting to be created, they are mature industries where bio-based alternatives can compete on cost and performance, with sustainability as a structural advantage.
The regulatory tailwind is real and growing. The Global Methane Pledge, EPA methane emissions rules, expanding satellite monitoring networks, and carbon credit markets all create increasing economic pressure to capture methane rather than release it. Companies that convert captured methane into saleable products stack product revenue on top of regulatory compliance value.
Why this matters even more now
The political and policy environment makes domestic biomanufacturing more urgent than ever.
In December 2025, the FY2026 National Defense Authorization Act included 17 provisions designed to elevate biotechnology across the defense and intelligence communities, including the creation of a Biotechnology Supply Chain Resiliency Program authorizing the DOD to accelerate domestic biomanufacturing solutions. A February 2026 GAO report found that DOD has invested $965 million in biomanufacturing since 2021, while acknowledging that the U.S. still lacks sufficient infrastructure to advance biotechnology projects from lab to commercial scale. The bipartisan Biomanufacturing Excellence Act of 2025 proposes a national center of excellence to strengthen domestic production capacity.
The supply-chain tailwind is growing as well. Supply-chain disruptions and geopolitical fragmentation have increased pressure for resilience-oriented reconfiguration, including diversification, near/friend-shoring, and selective domestic capacity-building in strategic sectors . Methane is well-positioned to support localized feedstock strategies because it can be sourced from natural gas and biogenic streams, including landfill-derived gas, and is increasingly being explored as an input for higher-value outputs.
Meanwhile, the NSCEB continues its “Biotech Across America Roadshow,” warning that the U.S. has a roughly three-year window to act before falling irreversibly behind China in biomanufacturing capacity. China has launched the world’s largest coordinated biomanufacturing buildout, 43 companies across 37 industry directions, and has positioned industrial biotech as a Politburo Standing Committee priority.
As we wrote in our December newsletter, this is a familiar pattern: a critical upstream technology gets cornered by whoever scales fastest and invests most deliberately. The difference is that in biomanufacturing, the U.S. still has a significant innovation advantage. Whether that innovation gets manufactured here, at scale, on competitive terms, or commercialized elsewhere, depends on the decisions made in the next few years.
For early-stage investors like us, this convergence of low-cost feedstock, massive markets, accelerating regulation, bipartisan policy support, and national security urgency creates a window that is opening now.
What we’re building toward
We’re tracking the entire methane-to-products ecosystem: companies converting methane into protein for aquaculture, into bioplastics, into drop-in fuels, and into chemical building blocks. With a biological emphasis, we’re interested in companies that have engineered the methanotroph for methane fixation in plants, bioreactors, soil, and even forest contexts.
More broadly, we’re interested in investing in use cases that take advantage of methane’s real thermodynamic edge. Methane is a single-carbon, hydrogen-rich feedstock, which makes it especially well suited to produce products like hydrogen, methanol, and the reducing gases used in lower-carbon steelmaking. In other words, some of the strongest demand tailwinds for methane are not in trying to force it into every downstream category, but in building around the products methane is naturally best positioned to make.
We’re also watching methane pyrolysis and methane-derived carbon materials as meaningful sources of optionality. Pyrolysis can co-produce hydrogen alongside solid carbons such as graphitic carbons and nanotubes, which could become more valuable as battery demand rises and graphite supply remains concentrated.
With biological emphasis, we’re interested in companies that have engineered the methanotroph in plants, bioreactors, soil, and even forest contexts.
As we think about the next generation of companies in this space, we believe the winners won’t just be the ones that can capture methane but will be the ones that can route it into the highest-value end markets, especially where biology can unlock feedstocks that conventional infrastructure still treats as too small, too dirty, or too distributed to matter. And the opportunity is broader than molecules alone: in a world increasingly shaped by energy security, affordability, and competitiveness, methane also has value as a localized industrial input. Industrial biology sits at the center of that shift.
The broader market signal is still hard to ignore, even if U.S. support for some clean energy categories has become less consistent. The IEA projects USD 3.3 trillion of global energy investment in 2025, including roughly USD 2.2 trillion for clean energy, suggesting that the structural drivers behind the transition, resilience, energy security, and industrial competitiveness, remain intact. We believe methane-to-products is especially relevant in that context because it is not just a decarbonization story; it is also a domestic feedstock, manufacturing, and resource-efficiency story.
If you’re building in this space, we want to hear from you!
Upcoming events
Juniper is co-hosting a couple of events with Lichen Ventures the week of April 20th in Washington, D.C., for DC Climate Week. We would love to have you join us at any of the following: